Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Emerg Med J ; 22(7): 473-7, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15983080

ABSTRACT

OBJECTIVE: To describe the emergency department (ED) management of isolated mild traumatic brain injury (TBI) in the USA and to examine variation in care across age and insurance types. METHODS: A secondary analysis of ED visits for isolated mild TBI in the National Hospital Ambulatory Medical Care Survey 1998-2000 was performed. Mild TBI was defined by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes for skull fracture, concussion, intracranial injury (unspecified), and head injury (unspecified). Available ED care variables were analysed by patient age and insurance categories using multivariate logistic regression. RESULTS: The incidence of isolated mild TBI cases attending ED was 153,296 per year, or 56.4/100,000 people. Of the patients with isolated mild TBI, 44.3% underwent computed tomography, 23.9% underwent other non-extremity, non-chest x rays, 17.1% received wound care and 14.1% received intravenous fluids. However, only 43.8% had an assessment of pain. Of those with documented pain, only 45.5% received analgesics in the ED. Nearly 38% were discharged without recommendations for specific follow up. Several aspects of ED care varied by age but not by insurance type. CONCLUSION: Substantial ED resources are devoted to the care of isolated mild TBI. The present study identified deficiencies in and variation around several important aspects of ED care. The development of guidelines specific for mild TBI could reduce variation and improve emergency care for this injury.


Subject(s)
Brain Injuries/therapy , Emergency Service, Hospital , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Analgesics/administration & dosage , Brain Injuries/diagnosis , Brain Injuries/epidemiology , Child , Child, Preschool , Female , Health Care Surveys , Hospitalization/statistics & numerical data , Humans , Incidence , Infant , Infant, Newborn , Male , Middle Aged , Patient Discharge , Professional Practice/statistics & numerical data , United States/epidemiology
2.
Am J Hematol ; 58(4): 293-7, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9692392

ABSTRACT

The purpose of this study was to test the comparative efficacy and toxicity of empiric gentamicin and ciprofloxacin, in combination with piperacillin, in febrile patients with treatment-induced neutropenia. Fifty patients were prospectively randomized to receive piperacillin plus gentamicin (PG), and 46 were randomized to receive piperacillin plus ciprofloxacin (PC). The groups were similar in age, sex, diagnosis, duration of neutropenia, and incidence of positive cultures. The two antibiotic regimens were associated with comparable rates of defervescence in the patients with gram-positive bacteremia. In the patients with gram-negative bacteremia and those with negative cultures, however, defervescence was more prompt in the PC group. In particular, 27% of the culture-negative patients on PC, compared to only 5% of those on PG, defervesced within 72 hr (P = 0.015). Because of the more prompt defervescence in the PC group, amphotericin B was used less frequently; 78% of the patients on PG compared with only 56% of those on PC were started on amphotericin B (P = 0.025). PC is an effective alternative to the more traditional PG for treatment of febrile neutropenic hosts who have not been given prophylactic quinolones. More important, PC appears to hasten defervescence compared with PG, especially in culture-negative patients and those with gram-negative bacteremia, and may decrease the necessity of additional antimicrobial agents such as amphotericin B.


Subject(s)
Ciprofloxacin/therapeutic use , Drug Therapy, Combination/therapeutic use , Fever/drug therapy , Neutropenia/drug therapy , Piperacillin/therapeutic use , Adult , Amphotericin B/therapeutic use , Bacterial Infections/blood , Ciprofloxacin/adverse effects , Drug Therapy, Combination/adverse effects , Female , Gentamicins/adverse effects , Gentamicins/blood , Gentamicins/therapeutic use , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Mycoses/blood , Piperacillin/adverse effects , Prospective Studies , Time Factors , Vancomycin/therapeutic use
3.
Bone Marrow Transplant ; 19(9): 883-90, 1997 May.
Article in English | MEDLINE | ID: mdl-9156261

ABSTRACT

One hundred and thirty-six patients autografted for relapsed or refractory non-Hodgkin's lymphoma (NHL) were evaluated to assess long-term event-free survival and to identify important prognostic factors. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem cell rescue. The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 34% (95% confidence interval: 24-44%) with a median follow-up of approximately 3 years (range 0-7.5 years). For patients entering with minimal disease (defined as all areas < or = 2 cm), the 5-year EFS was 40 vs 26% for those entering with bulky disease (P = 0.0004). In the multivariate analysis, minimal disease on entry and administration of involved-field XRT post-transplant were significantly associated with improved EFS; the latter association was observed mainly in the cohort of patients with bulky disease. The overall 100-day treatment-related mortality rate was 4.4% (3% for the last 71 patients). New strategies are needed to reduce the high rate of relapse (50-60%) following auto-transplantation for relapsed or refractory NHL.


Subject(s)
Bone Marrow Transplantation , Lymphoma, Non-Hodgkin/therapy , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Multivariate Analysis , Neoplasm, Residual , Prognosis , Recurrence , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...